Document is current
Any future updates will be listed below
-
Authors
Bai, Ren-Yuan https://orcid.org/0000-0001-5281-9091
Shi, Jingyi
Liu, Jianan
Sun, Nihao
Lu, Yuqing
Chen, Xiaojun https://orcid.org/0009-0007-9098-1680
Xu, Manzhu
Lim, Hotae
Li, Yang
Xu, Huazhen
Weisgerber, Karis
Ren, Zhihong
Pratilas, Christine A. https://orcid.org/0000-0002-7116-0605
Blakeley, Jaishri O. https://orcid.org/0000-0002-1049-0993
Fishel, Melissa L. https://orcid.org/0000-0002-9436-6382
Carrió, Meritxell
Serra, Eduard https://orcid.org/0000-0003-2895-9857
Staedtke, Verena
-
Funding
Funding for this research was provided by:
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (W81XWH1810236)
Sontag Foundation (Distinguished Scientist Award)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1K08CA230179, 5U01CA247576)
- License Information
-
More Information
Article History
Received: 15 October 2024
Accepted: 18 August 2025
First Online: 29 September 2025
Competing interests
: A patent application on the new AAV vectors for NF1 gene replacement therapy with R.B. and V.S. as co-inventors has been provisionally filed by JHU (63/697,752). The remaining authors declare no competing interests.
